PROTECTIVE ROLE OF SAFFRON TO REDUCE INFLAMMATION AND IMPROVE CLINICAL MANIFESTATIONS IN ULCERATIVE COLITIS PATIENTS

Hassan Ashktorab,Roham Salman Roghani,Hassan Rohgani,Lakshmi Chirumamilla,Nasrin Farjana,Mudasir Rashid,Farshad Aduli,Angesom Kibreab,Adeyinka Laiyemo,Suryanarayana Reddy Challa,Philip Oppong-Twene,Hassan Brim

DOI: https://doi.org/10.1093/ibd/izae020.021

2024-01-25

Inflammatory Bowel Diseases

Abstract:Abstract BACKGROUND We studied saffron as an additional intervention to improve clinical manifestations of Ulcerative colitis (UC) patients. METHODS This is a study at Yazd university where 30 UC patients were randomly assigned to placebo (n=9), low (n=9, 25 mg), or high dose saffron (n=12, 50mg), two times a day for 8 weeks. Hemoglobin, platelet levels, CRP, ESR, and fecal calprotectin along with clinical data Simple Clinical Colitis Activity Index (SCCAI), Partial Mayo Score, and Hamilton Depression Anxiety Score (HDRS) were recorded at baseline and completion of treatment. For validation, we recruited 3 UC patients at Howard University who received 50mg of Saffron twice daily for 8 weeks, two underwent a wash-out period and received saffron for a second cycle. Inflammatory markers, CRP, stool calprotectin, and the cytokines from PMA/ionomycin stimulated PBMCs, at baseline and 8 weeks Saffron treatment were compared. 16S rDNA analysis was performed on stool DNA for gut microbiome. RESULTS In Yazd study of 30 patients, all participants completed the study successfully. The high dose group showed significant improvement in HDRS score (p=0.001), SCCAI (p=0.04), Partial Mayo score (p=0.01), fecal calprotectin (p=0.009), and CRP (p=0.001) compared to baseline. The low dose group also improved in HDRS score (p=0.01; Table 1, Fig 1). No adverse events were reported. In HU data, saffron improved Partial Mayo Score, health related quality of life and HDRS. Pro-inflammatory cytokines TNFα, INFγ, IL-6, IL-2, IL-17a decreased while anti-inflammatory IL-10, TGF-β increased. Fecal calprotectin levels of 228 μg/g and 169 μg/g decreased to 63 μg/g and 16 μg/g in two individual patients, respectively. After the wash-out period, fecal calprotectin increased. A second saffron treatment cycle reduced it again further validating the causal relationship. Saffron led to a decrease in gamma Proteobacteria, and enrichment in Ruminococcaceae. CONCLUSION This study demonstrates that saffron led to improvements in clinical response including reduction in partial Mayo scores, HDRS scores, and inflammatory markers such as fecal calprotectin and CRP. These findings suggest that the use of saffron supplements alongside standard treatment protocols may yield beneficial effects for individuals with UC. Table 1. Basic characteristics, clinical variables, and laboratory variables among the study participants in three arms of the clinical trial. Figure 1 Effect of Saffron on quality of life and Inflammatory markers.

gastroenterology & hepatology

What problem does this paper attempt to address?

### Problems the Papers Try to Solve

#### The First Paper
**Title**: Maintenance Efficacy of Oral Indigo in the Treatment of Ulcerative Colitis: A Single - Center, Open - Label, Randomized Controlled Study

**Background**: Indigo naturalis (IN), a traditional Chinese medicine, has shown significant effects in induction remission treatment. However, its effect in the maintenance treatment of ulcerative colitis (UC) has not been clear yet.

**Objective**: This study aims to explore the effect of indigo in the maintenance treatment of UC.

#### The Second Paper
**Title**: The Protective Role of Saffron in Reducing Inflammation and Improving Clinical Manifestations in Patients with Ulcerative Colitis

**Background**: Researchers have studied saffron as an auxiliary intervention method to improve the clinical manifestations of UC patients.

**Objective**: To evaluate the improvement effect of saffron on the inflammation indicators and clinical symptoms of UC patients.

#### The Third Paper
**Title**: Dose Escalation of Subcutaneous Infliximab (CT - P13 SC) as an Option for Managing Non - Response in Inflammatory Bowel Disease: Post - Hoc Analysis of the LIBERTY - UC and LIBERTY - CD Studies

**Background**: Dose escalation of intravenous infliximab (IV infliximab) is an option for patients with inflammatory bowel disease (IBD) who do not respond after induction treatment. However, data on dose escalation of subcutaneous infliximab (CT - P13 SC) are limited.

**Objective**: Through post - hoc analysis, to evaluate the efficacy, safety and immunogenicity of dose escalation of subcutaneous infliximab in IBD patients, especially for those who initially responded but later lost their response.

### Summary
These three papers focus on the applications of different treatment methods in ulcerative colitis and inflammatory bowel disease respectively:
1. **Indigo**: To study its effect in the maintenance treatment of UC.
2. **Saffron**: To evaluate its clinical effect as an auxiliary treatment method in UC patients.
3. **Subcutaneous infliximab**: To explore its efficacy and safety of dose escalation in IBD patients.